Results 51 to 60 of about 5,314 (201)

Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients

Perspectives in Clinical Research, 2021
Context: The Indian government is dispensing newer direct-acting antiviral (DAA) drugs, which may have impact on hepatitis C virus (HCV) patients’ quality of life (QoL).
Bhavya H Vyas, Nishita H Darji, Devang A Rana, Kaushal Y Vyas, Supriya D Malhotra   +4 more
doaj   +1 more source

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C

International Journal of General Medicine, 2021
Lu-Hua Gao, Qing-He Nie, Xi-Tai Zhao Center of Infectious Diseases, Second Affiliated Hospital, Air-Force Military Medical University, Xi’an 710038, People’s Republic of ChinaCorrespondence: Qing-He NieCenter of Infectious Diseases, Second ...
Gao LH, Nie QH, Zhao XT
doaj  

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Hepatitis C Virus Infection in Pregnant Women - Current Treatment Practices

Quality in Sport
Hepatitis C Virus (HCV) is a single-stranded RNA virus with hepatotropic potential classified within the Flaviviridae family. HCV infection still remains a global problem.
Magdalena Zapalska, Barbara Izabela Krupska , Julia Anna Malec , Lidia Kulig, Franciszek Włodarczyk, Weronika Maria Woźniak, Marcin Wieleba, Zuzanna Winiarska, Katarzyna Wiktoria Witczak, Eliza Wiercioch   +9 more
doaj   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study [PDF]

, 2018
AIM: To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Russo, Francesco Paolo, Senzolo, Marco, Shalaby, Sarah, Zanetto, Alberto, Zanus, Giacomo   +10 more
core   +1 more source

Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications

Portal Hypertension &Cirrhosis, Volume 5, Issue 1, Page 65-95, March 2026.
Primary liver cancer remains a major global health burden, with China accounting for over 40% of cases. The predominant etiology is shifting from viral hepatitis to metabolic dysfunction‐associated steatotic liver disease (MASLD), while aflatoxin exposure and unhealthy lifestyles remain important contributors. Comprehensive control strategies—including
Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou   +12 more
wiley   +1 more source

Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review

Revista de Gastroenterología de México (English Edition), 2022
Introduction: The sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12
J.L. Pérez-Hernández, C.A. Arce-Salinas, R. Lehmann-Mendoza, A. Torre-Delgadillo, G.E. Castro-Narro, E. Cerda-Reyes, M.V. Ramos-Gómez, L. Juárez-Chavez, M. Dehesa-Violante, L.E. Muñoz-Espinoza, L.E. Cisneros-Garza, I. Aiza-Haddad, J.A. Velarde-Ruiz-Velasco, R. Contreras-Omaña, N. García-Casarreal, A. Carmona-Castañeda, F. Higuera-De la Tijera   +16 more
doaj   +1 more source

Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents [PDF]

, 2018
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked FilesA nationwide programme for the treatment of all patients infected with hepatitis
Bergmann, O. M., Björnsson, E. S., Fridriksdottir, R. H., Gottfredsson, M., Gudnason, T., Hansdottir, I., Heimisdottir, M., Hellard, M., Johannsson, B., Löve, A., Löve, T. J., Olafsson, S., Runarsdottir, V., Sigurdardottir, B., Tyrfingsson, T.   +14 more
core   +1 more source